Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL13280294 | 0.91 | LMNA (0.46) | ALDH1A1PRKCATDP1KMT2AMAPK1 | |
| SCHEMBL8922492 | 0.90 | ALDH1A1 (0.41) | ALDH1A1PRKCATDP1KMT2ASLC6A2 | |
| SCHEMBL697738 | 0.84 | ALDH1A1 (0.53) | ALDH1A1PRKCATDP1KMT2AMAPK1 | |
| SCHEMBL4372826 | 0.83 | ALDH1A1 (0.47) | ALDH1A1PRKCATDP1MAPK1LMNA | |
| SCHEMBL6917169 | 0.82 | MAPT (0.49) | ALDH1A1PRKCAKMT2ALMNAADRB2 | |
| SCHEMBL3894587 | 0.82 | PRKCA (0.36) | ALDH1A1PRKCATDP1KMT2ASLC6A2 | |
| SCHEMBL62519 | 0.82 | LMNA (0.51) | ALDH1A1PRKCAKMT2ASLC6A3LMNA | |
| SCHEMBL28059255 | 0.82 | ALDH1A1 (0.51) | ALDH1A1PRKCATDP1KMT2AMAPK1 | |
| SCHEMBL697737 | 0.82 | ALDH1A1 (0.51) | ALDH1A1PRKCATDP1KMT2AMAPK1 | |
| SCHEMBL11715517 | 0.81 | ALDH1A1 (0.51) | ALDH1A1PRKCATDP1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374609-A1 | NITROSAMINE IMPURITY, VARENICLINE PHARMACEUTICAL COMPOSITION CAPABLE OF REDUCING GENERATION OF NITROSAMINE IMPURITIES AND PREPARATION AND USE THEREOF | VIWIT PHARMACEUTICALCO LTD (CN) | 2024-11-14 | — | — | US | claimed |
| EP-4389748-A2 | NITROSAMINE IMPURITY, VARENICLINE PHARMACEUTICAL COMPOSITION CAPABLE OF REDUCING GENERATION OF NITROSAMINE IMPURITIES AND PREPARATION AND USE THEREOF | Viwit Pharmaceutical Co., Ltd. (CN) | 2024-06-26 | — | — | EP | claimed |
| US-12016917-B2 | Peanut formulations and uses thereof | Société des Produits Nestlé S.A. (CH) | 2024-06-25 | — | — | US | claimed |
| CN-117715910-A | Nitrosamine impurity, valicarb pharmaceutical composition capable of reducing nitrosamine impurity generation, and preparation and application thereof | 威智医药股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-117442575-A | Vanilla pharmaceutical composition and preparation and application thereof | 山东威智中科药业有限公司 | 2024-01-26 | — | — | CN | claimed |
| US-20230139230-A1 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | AIMMUNE THERAPEUTICS, INC. | 2023-05-04 | — | — | US | claimed |
| CN-115721625-A | Pharmaceutical composition containing mirabegron and preparation and application thereof | 山东威智中科药业有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-115721724-A | Pharmaceutical composition containing secondary amine compound and preparation and application thereof | 山东威智中科药业有限公司 | 2023-03-03 | — | — | CN | claimed |
| CN-115707470-A | Vanillan pharmaceutical composition with low nitrosamine impurity content, and preparation method and application thereof | 山东威智中科药业有限公司 | 2023-02-21 | — | — | CN | claimed |
| CN-113908131-A | Vanillan pharmaceutical composition capable of reducing production of nitrosamine impurities and preparation and application thereof | 山东威智中科药业有限公司 | 2022-01-11 | — | — | CN | claimed |
| US-20160051593-A1 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | Société des Produits Nestlé S.A. (CH) | 2016-02-25 | — | — | US | claimed |
| US-20160051639-A1 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | AIMMUNE THERAPEUTICS, INC. | 2016-02-25 | — | — | US | claimed |
| WO-2015187736-A1 | PLACEBO FORMULATIONS AND USES THEREOF | Allergen Research Corporation (US) | 2015-12-10 | — | — | WO | claimed |
| US-20150343075-A1 | PLACEBO FORMULATIONS AND USES THEREOF | AIMMUNE THERAPEUTICS, INC. | 2015-12-03 | — | — | US | claimed |
| WO-2014159609-A1 | PEANUT FORMULATIONS AND USES THEREOF | Allergen Research Corporation (US) | 2014-10-02 | — | — | WO | claimed |
| US-20140271721-A1 | PEANUT FORMULATIONS AND USES THEREOF | Allergen Research Corporation (US) | 2014-09-18 | — | — | US | claimed |
| US-5807540-A | Nail varnish composition comprising a crosslinked polyester | L'OREAL (FR) | 1998-09-15 | — | — | US | claimed |
| EP-0740933-B1 | Nail varnish composition containing a crosslinked polyester | OREAL (FR) | 1997-03-26 | — | — | EP | claimed |
| US-5336692-A | High-molecular-weight petrolatum, solvent and a compound both hydrophobic and hydrophilic; protective coatings for skin; moisturizers; spreadability; long-lasting | MEDICIS PHARMACEUTICAL CORPORATION (US) | 1994-08-09 | — | — | US | claimed |
| WO-1992000077-A1 | IMPROVED OINTMENT BASE AND METHOD OF USE | MEDICIS CORPORATION (US) | 1992-01-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160051593-A1 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | ALB, SON, MAX | ALDH1A1 4776/4885PRKCA 1243/4885TDP1 4771/4885 |
| US-20240374609-A1 | NITROSAMINE IMPURITY, VARENICLINE PHARMACEUTICAL COMPOSITION CAPABLE OF REDUCING GENERATION OF NITROSAMINE IMPURITIES AND PREPARATION AND USE THEREOF | UGT2B7, CYP3A7, CYP2C9 | ALDH1A1 318/4885PRKCA 1201/4885TDP1 74/4885 |
| US-20230139230-A1 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | ALB, SON, MAX | ALDH1A1 4776/4885PRKCA 1243/4885TDP1 4771/4885 |
| US-20160051639-A1 | EGG PROTEIN FORMULATIONS AND METHODS OF MANUFACTURE THEREOF | ALB, SON, MAX | ALDH1A1 4776/4885PRKCA 1243/4885TDP1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.